This cohort study examines whether cancer immunotherapy effectiveness varies between female and male patients with advanced melanoma treated with either nivolumab plus ipilimumab combination therapy or anti–programmed cell death protein 1 therapy. This evidence concerns the gene PDCD1 and cancer.